

# Accepted Manuscript



Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

Norah Terrault, Yi-Cheng Chen, Namiki Izumi, Zeid Kayali, Paul Mitrut, Won Young Tak, Lee F. Allen, Tarek Hassanein

PII: S0016-5085(18)34545-1  
DOI: [10.1053/j.gastro.2018.05.025](https://doi.org/10.1053/j.gastro.2018.05.025)  
Reference: YGAST 61891

To appear in: *Gastroenterology*  
Accepted Date: 11 May 2018

Please cite this article as: Terrault N, Chen Y-C, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T, Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia, *Gastroenterology* (2018), doi: 10.1053/j.gastro.2018.05.025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title:** Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia

**Short title:** Avatrombopag before procedures in CLD

Norah Terrault,<sup>1</sup> Yi-Cheng Chen,<sup>2</sup> Namiki Izumi,<sup>3</sup> Zeid Kayali,<sup>4</sup> Paul Mitrut,<sup>5</sup> Won Young Tak,<sup>6</sup> Lee F Allen,<sup>7</sup> and Tarek Hassanein<sup>8</sup>

<sup>1</sup>University of California San Francisco, San Francisco, CA, USA; <sup>2</sup>Chang Gung Memorial Hospital and University, Taoyuan, Taiwan; <sup>3</sup>Musashino Red Cross Hospital, Tokyo, Japan; <sup>4</sup>Inland Empire Liver Foundation, Rialto, CA, USA; <sup>5</sup>University of Medicine and Pharmacy of Craiova, Craiova, Romania; <sup>6</sup>Kyungpool National University, Daegu, Korea; <sup>7</sup>Dova Pharmaceuticals, Durham, NC, USA; <sup>8</sup>Southern California GI and Liver Centers, Coronado, CA, USA

**Grant support:** N/A

**Abbreviations:** AE, adverse event; AESI, adverse event of special interest; CLD, chronic liver disease; PD, pharmacodynamics; PK, pharmacokinetic; TEAE, treatment-emergent adverse event; WHO, World Health Organization.

**Corresponding author and contact details:**

Norah Terrault, MPH, MD

University of California San Francisco, San Francisco, CA, USA

Email: [Norah.Terrault@ucsf.edu](mailto:Norah.Terrault@ucsf.edu)

**Disclosures/conflict of interest statement:** N.T. has received research grants from AbbVie, Allergan, BMS, Eisai, Gilead, and Merck.

Y.C. has nothing to disclose.

N.I. has received grants from AbbVie, Bayer, Gilead, Otsuka, and Shionogi.

Z.K. has received grants from BMS, Eisai, Exelixis, Gilead, Intercept, Merck, Novartis, Pfizer, Shionogi, and Shire.

P.M. has nothing to disclose.

Download English Version:

<https://daneshyari.com/en/article/8957688>

Download Persian Version:

<https://daneshyari.com/article/8957688>

[Daneshyari.com](https://daneshyari.com)